GlassScriptPhysician profile
Mariana Nelson
NPI 1578175097
$2,392.28
in general payments reported to CMS, 2019-2025
25 companies · $534 in 2025
The $534 reported for 2025 was more than what 76% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $357 · 2022: $160 · 2023: $415 · 2024: $927 · 2025: $534.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,876.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,876.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $372.19 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $247.58 | 2021-2025 | Farxiga, Wainua |
| Merck Sharp & Dohme LLC | $225.83 | 2021-2025 | Verquvo |
| Abbott Laboratories | $218.97 | 2023-2025 | Gallant, Ensite, Ensite Precision |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $178.46 | 2022-2024 | Lifevest |
| Amgen INC. | $134.45 | 2023-2025 | Repatha |
| Glaxosmithkline, LLC. | $123.95 | 2023 | |
| Pfizer INC. | $116.56 | 2022-2024 | |
| Abbvie INC. | $115.00 | 2021 | |
| Abiomed | $86.71 | 2024-2025 | Impella |
| Kiniksa Pharmaceuticals International, Plc | $79.14 | 2024 | Arcalyst |
| Boehringer Ingelheim Pharmaceuticals, INC. | $78.80 | 2024-2025 | Jardiance |
| Scpharmaceuticals INC. | $76.59 | 2024-2025 | |
| Esperion Therapeutics, INC. | $50.39 | 2021 | |
| Inspire Medical Systems, INC. | $46.45 | 2024-2025 | Inspire |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $38.73 | 2023 | |
| Medtronic, INC. | $31.13 | 2023-2025 | Corevalve Evolut R, Venaseal |
| Heartflow, INC. | $30.17 | 2025 | |
| Biotronik INC. | $26.98 | 2025 | Acticor 7 Vr-T Dx |
| Irhythm Technologies, INC. | $25.61 | 2022 | |
| Cvrx, INC. | $25.58 | 2024 | Barostim Neo System |
| Shockwave Medical, INC | $21.03 | 2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Altathera Pharmaceuticals LLC | $18.08 | 2025 | Sotalol Hydrochloride |
| Bayer Healthcare Pharmaceuticals INC. | $12.62 | 2021 | |
| Kiniksa Pharmaceuticals, LTD. | $11.28 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mariana Nelson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.